Development of a prognostic model of overall survival in oropharyngeal cancer from real-world data: PRO.M.E.THE.O.
cetuximab
head and neck tumour
personalised medicine
prediction model
Journal
Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale
ISSN: 1827-675X
Titre abrégé: Acta Otorhinolaryngol Ital
Pays: Italy
ID NLM: 8213019
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
06
05
2021
accepted:
11
10
2021
pubmed:
10
4
2022
medline:
28
7
2022
entrez:
9
4
2022
Statut:
ppublish
Résumé
The PRO.M.E.THE.O. study (PredictiOn Models in Ent cancer for anti-EGFR based THErapy Optimization) aimed to develop a predictive model (PM) of overall survival (OS) for patients with locally advanced oropharyngeal cancer (LAOC) treated with radiotherapy (RT) and cetuximab (Cet) from an Italian dataset. We enrolled patients with LAOC from 6 centres treated with RT-Cet. Clinical and treatment variables were collected. Patients were randomly divided into training (TS) (80%) and validation (VS) (20%) sets. A binary logistic regression model was used on the TS with stepwise feature selection and then on VS. Timepoints of 2, 3 and 5 years were considered. The area under the curve (AUC) of receiver operating characteristic of 2, 3 and 5 year and confusion matrix statistics at 5-threshold were used as performance criteria. Overall, 218 patients were enrolled and 174 (79.8%) were analysed. Age at diagnosis, gender, ECOG performance, clinical stage, dose to high-risk volume, overall treatment time and day of RT interruption were considered in the final PMs. The PMs were developed and represented by nomograms with AUC of 0.75, 0.73 and 0.73 for TS and 0.713, 0.713, 0.775 for VS at 2, 3 and 5 years, respectively. PRO.M.E.THE.O. allows the creation of a PM for OS in patients with LAOC treated with RT-Cet. Sviluppo di un modello predittivo in pazienti affetti da neoplasia dell’orofaringe: PRO.M.E.THE.O. L’obiettivo di PRO.M.E.THE.O. è quello di sviluppare modelli predittivi (MP) di sopravvivenza globale (OS) per pazienti (pz) con neoplasia orofaringea localmente avanzata (LAOC) sottoposti a radioterapia (RT) e Cetuximab (Cet), provenienti da un dataset italiano multicentrico. Sono stati arruolati pazienti con LAOC trattati con RT-Cet provenienti da 6 centri italiani, dei quali sono state raccolte variabili cliniche e di trattamento. I pazienti sono stati suddivisi casualmente in un training set (80%) e in un gruppo di controllo (20%). Per la creazione del MP è stata considerata l’OS a 2, 3 e 5 anni. L’area sottesa alla curva (AUC) di ROC (receiver operating characteristic) a 2, 3 e 5 anni e la statistica della matrice di confusione a 5 classi rappresentano i criteri di performance. 218 pazienti sono stati arruolati e 174 (79,8%) analizzati. I parametri testati per la costruzione degli MP includevano: età alla diagnosi, sesso, ECOG, stadio clinico, dose del volume ad alto rischio, tempo complessivo di trattamento e giorni di interruzione della RT. I MP di OS sono stati rappresentati con dei nomogrammi. PRO.M.E.THE.O. ha consentito la creazione di MP di OS in pazienti LAOC trattati con RT-Cet.
Autres résumés
Type: Publisher
(ita)
Sviluppo di un modello predittivo in pazienti affetti da neoplasia dell’orofaringe: PRO.M.E.THE.O.
Identifiants
pubmed: 35396587
doi: 10.14639/0392-100X-N1672
pmc: PMC9330744
doi:
Substances chimiques
Cetuximab
PQX0D8J21J
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
205-214Informations de copyright
Copyright © 2022 Società Italiana di Otorinolaringoiatria e Chirurgia Cervico-Facciale, Rome, Italy.
Références
Radiother Oncol. 2011 Jan;98(1):126-33
pubmed: 21176986
J Clin Oncol. 2017 Dec 20;35(36):4057-4065
pubmed: 28777690
J Clin Oncol. 2010 Mar 10;28(8):1380-6
pubmed: 20142596
Radiother Oncol. 2011 Jul;100(1):33-40
pubmed: 21684027
J Contemp Brachytherapy. 2016 Aug;8(4):336-43
pubmed: 27648088
Radiother Oncol. 2021 Mar;156:281-293
pubmed: 33515668
J Clin Oncol. 2016 Feb 10;34(5):427-35
pubmed: 26644536
Cancer. 2019 Jan 1;125(1):68-78
pubmed: 30291798
Lancet. 2019 Jan 5;393(10166):51-60
pubmed: 30449623
Radiother Oncol. 2014 Dec;113(3):324-30
pubmed: 25443497
N Engl J Med. 2006 Feb 9;354(6):567-78
pubmed: 16467544
Lancet Oncol. 2017 Feb;18(2):202-211
pubmed: 27993569
BMJ. 2015 Jan 07;350:g7594
pubmed: 25569120
Radiother Oncol. 2015 Jan;114(1):132-4
pubmed: 25616538
J Contemp Brachytherapy. 2018 Jun;10(3):260-266
pubmed: 30038647
Lancet. 2019 Jan 5;393(10166):40-50
pubmed: 30449625
Lancet Oncol. 2010 Jan;11(1):21-8
pubmed: 19897418
Oral Oncol. 2018 Aug;83:73-80
pubmed: 30098782
Acta Oncol. 2013 Nov;52(8):1676-81
pubmed: 23336255
Cancer Causes Control. 2017 Oct;28(10):1085-1093
pubmed: 28815336
Radiother Oncol. 2014 Jul;112(1):59-62
pubmed: 24853366
Front Oncol. 2020 Jan 22;9:1522
pubmed: 32039012
Int J Radiat Biol. 1999 Apr;75(4):513-7
pubmed: 10331857
J Natl Cancer Inst. 2020 Aug 1;112(8):855-858
pubmed: 31747025